期刊
CELL REPORTS
卷 37, 期 6, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.celrep.2021.109979
关键词
-
类别
资金
- BBSRC
- Wellcome
- University of Manchester Strategic Fund
- Christie Charitable Fund
- CRUK Manchester Institute [A20971, A27412]
- Manchester CRUK Centre Award [A25254]
- CRUK Manchester Experimental Cancer Medicines Centre [A25146]
- CRUK Lung Cancer Centre of Excellence [A20465]
The study shows that the TIAM1-RAC1 signaling pathway promotes survival of SCLC cells through nuclear sequestration of Nur77.
Small-cell lung cancer (SCLC), an aggressive neuroendocrine malignancy, has limited treatment options beyond platinum-based chemotherapy, whereafter acquired resistance is rapid and common. By analyzing expression data from SCLC tumors, patient-derived models, and established cell lines, we show that the expression of TIAM1, an activator of the small GTPase RAC1, is associated with a neuroendocrine gene program. TIAM1 depletion or RAC1 inhibition reduces viability and tumorigenicity of SCLC cells by increasing apoptosis associated with conversion of BCL2 from its pro-survival to pro-apoptotic function via BH3 domain exposure. This conversion is dependent upon cytoplasmic translocation of Nur77, an orphan nuclear receptor. TIAM1 interacts with and sequesters Nur77 in SCLC cell nuclei and TIAM1 depletion or RAC1 inhibition promotes Nur77 translocation to the cytoplasm. Mutant TIAM1 with reduced Nur77 binding fails to suppress apoptosis triggered by TIAM1 depletion. In conclusion, TIAM1-RAC1 signaling promotes SCLC cell survival via Nur77 nuclear sequestration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据